Ideas

 Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Elafibranor (GFT505), an experimental drug for diabetes, insulin resistance, dyslipidemia, nonalcoholic steatohepatitis (NASH), increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 31/January/2018, 6.00 am
 Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Elafibranor (GFT505), an experimental drug for diabetes, insulin resistance, dyslipidemia, nonalcoholic steatohepatitis (NASH), increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 31/January/2018, 6.00 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

read more

Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm
Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  probiotics Clostridium butyricum MIYAIRI 588 (CBM588) and Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as  BTG2, SMARCA4, p53 and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 30/January/2019, `7.38 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports here that: Probiotic-based therapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture…

read more

Molecular therapy for Autoimmune diabetes: AIRE (Autoimmune regulator) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 30/January/2019, 7.26 pm
Molecular therapy for Autoimmune diabetes: AIRE (Autoimmune regulator) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 30/January/2019, 7.26 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Ribonucleic acid-based therapy for myocardial diseases: LncRNA TUG1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 30/January/2018, 7.17 pm
Ribonucleic acid-based therapy for myocardial diseases: LncRNA TUG1-based therapy for Cardiac repair and myocardial infarction: LncRNA  TUG1 increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 30/January/2018, 7.17 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Natural product-based therapy for attenuating pathogenesis-associated with Myocardial infarction: Rutin decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via upregulation of its target gene, 29/January/2018, 7.36 am
Natural product-based therapy for attenuating pathogenesis-associated with Myocardial infarction: Rutin decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via upregulation of its target gene, 29/January/2018, 7.36 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA ARNILA (AR negatively induced lncRNA)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 29/January/2019, 6.35 am
Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA ARNILA (AR negatively induced lncRNA)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 29/January/2019, 6.35 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and Department of Pharmacology, School…

read more
Start Typing